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Honey promotes angiogeneic 
activity in the rat aortic ring assay
l objective: to investigate possible effects of honey on angiogenesis, using in vitro analogues of 
angiogenesis and an endothelial proliferation assay.
l Method: Using an in vitro rat aortic ring assay we compared pseudotubule formation by medicinal 
honey (Activon), supermarket honey (rowse) and a honey-based ointment (Mesitran), with that of 
artificial honey (70% w/w sugar glucose/fructose). Pseudotubules were analysed using tcS cellworks 
AngioSys software. the Angiokit sytem was used to validate the results. Using the Mtt 
[3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium. bromide] assay, toxicity was also assessed on 
human umbilical vein endothelial cells (HUvec) directly adherent to plastic.
l results: All honey preparations stimulated pseudotubule formation, maximal at around 0.2% honey. 
Medicinal honeys were more active than rowse. the effect was not attributable to the sugar content. 
Among the honeys tested, the Manuka-based Activon preparation reduced residual viable biomass 
compared with a sugar control at >0.32% v/v concentration. rowse had a similar effect only at 2.5%, the 
highest dose tested. 
l conclusion: the influence of honey constituents on angiogenesis in a wound dressing context is likely 
to be positive, but would depend on the effective dilution of the honey and the penetration of the active 
constituents against an osmotic gradient. the extent to which this occurs has yet to be established.
l conflict of interest: this work was conceived, designed and executed by the authors. Medical honey 
preparations were supplied unconditionally but free of charge by the distributors.
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 H
oney has been used in the treatment of 
wounds in many cultures for centuries, 
and is even mentioned in the Qur’an 
(Surah 16. Verse 68, 69, The Bee). 
Despite its antibacterial and antioxi-
dant properties, its use was superseded by modern 
dressing and antibiotics. However, due to the emer-
gence of antibiotic-resistant microorganisms and a 
growing interest in ‘natural’ medicines, honey has 
been rediscovered for the treatment of wounds.1  
The potential effect of topical application of hon-
ey on angiogenesis is severely under-investigated. 
Entering the words ‘angiogenesis’ and ‘honey’ 
together into PubMed yielded only two relevant ref-
erences.2,3 Hepsen et al. described the inhibitory 
effect of propolis (which is collected by bees and 
used as a cement in hive construction) on corneal 
neovascularisation in a rabbit corneal model,2 while 
Molan3 generalised that honey ‘…promotes tissue 
regeneration through stimulation of angiogenesis 
and the growth of fibroblasts and epithelial cells…’ 
He cited five references, which are all clinical and 
observational reports, as opposed to experimental 
or controlled clinical investigations. Two further 
references from this review, purporting to show 
experimental stimulation of angiogenesis by honey, 
in fact relate to the efficacy of indigenous drugs on 
infected wounds in buffalo.4,5 
Given the dearth of phenomenological evidence, 
we set out to produce some descriptive experiments 
using laboratory models of angiogenesis, in order to 
form a basis for future mechanistic studies. 
Materials and method
Honey types and characteristics
The honey types used in this study were:
l Artificial — an aqueous solution containing 
glucose (35% w/v) and fructose (35% w/v). We 
chose percentage weight per volume, as neat honey 
is too viscous to measure accurately by volume. 
Seventy grams of sugars were dissolved to make 
100ml final solution. This recipe conforms broadly 
with control preparations cited in the literature, 
which vary slightly in the proportions of sugars 
used; a typical example of control glucose/fructose 
solution is given by Osato et al.6 This artificial syrup 
acted as the control against hypertonic effects 
l Rowse — a supermarket honey. This was labelled 
as ‘a blend of E.C. (European Community) and non-
E.C. honeys’
l Mesitran ointment (Aspen Medical Europe, Red-
ditch) — a formulation containing honey, medical 
grade hypoallergenic lanolin, sunflower oil, cod liv-
er oil, Aloe barbadensis, vitamins C and E, and zinc 
oxide. The honey content is quoted as 47%
l Activon (Theo Manufacturing BV, Maastricht NL 
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and Advancis Medical Ltd, Nottingham UK): 
labelled as ‘a medical grade Manuka honey’. No 
ingredients other than Manuka honey are listed for 
this product.
Honey dilutions
Because the viscosity of raw honey makes volumet-
ric dispensing impossible, the initial honey dilution 
was made to 5% on a w/v (weight per cent [mass of 
solute (g) / volume of solution (ml)] x 100)) basis. 
Put simply, 5g honey were used per 100ml final vol-
ume. Thereafter, dilutions were prepared on a more 
conventional v/v (volume per cent [volume of sol-
ute (ml) / volume of solution (ml)] x 100)) basis.
For angiogenic assays, a five-fold dilution series 
was used (to cover a wide range of concentrations 
between 5–0.008% v/v in 5 steps); for the cytotoxic-
ity experiments, doubling dilutions were effected in 
situ in accordance with our normal published prac-
tice.7 All dilutions were made in Medium 200 
(an endothelial cell culture medium used for cell 
maintenance [TCS Cellworks, Buckingham, UK]). 
All dilutions are expressed as of neat preparation. 
Mesitran’s lower honey content was not compen-
sated for. 
cytotoxicity assay
Preparation methodology is outlined in Table 1. In 
terms of the products used:
l All reagents were purchased from Sigma Aldrich, 
unless otherwise stated
l TCS Cellworks provided the human umbilical 
vein endothelial cells (HUVEC from pooled donor) 
l EDTA solution was provided by Sigma Aldrich, 
Poole, Dorset, UK
l The spectrophotometric plate reader was a Bio-Tek 
Powerwave 340 
l Nunc 96-well adherent-cell culture-grade plates 
were used.
Results are expressed as toxicity (% inhibition 
against control growth, or 100 minus % residual 
viable biomass (RVB)). 
Table 1. Preparation methodology for the cytotoxicity and angiogenesis assays.
cytotoxicity assay
Human umbilical vein endothelial cells were maintained 
adherent to plastic in Medium 200 (tcS cellworks) and 
passaged using single strength trypsin-
ethylenediaminetetraacetic acid (eDtA) solution  
      
      
cells were seeded into 96-well adherent cell culture-
grade plates (5x103/well) and left to settle for 24 hours 
      
      
  
Well columns were filled with 100µl of honey solutions. 
columns 11 and 12 were used for 100% growth and 
blank controls (filled only with Medium 200) respectively
Plates were incubated for 1 hour at 37ºc and 5% co2, 
washed with PbS and re-filled with 150µl of fresh culture 
medium     
      
    
After incubation for a further 48 hours, 50µl of 1mg/ml 
Mtt8 were added for two hours’ incubation. the 
supernatant was discarded and the blue formazan 
product made within viable cells was solubilised with the 
addition of a 150µl of dimethyl sulphoxide (DMSo)  
per well
the plate was shaken and the developed colour read by 
absorbance at 570nm in a standard spectrophotometric 
plate reader (bio-tek Powerwave 340)
angiogenesis assays
Frozen matrigel was equilibrated to its liquid state 
overnight on ice, and maintained until needed. 200μl was 
transferred into the central 24 wells of a 48-well plate on 
ice. the outer wells were filled with saline to act as a 
barrier to evaporation artefacts and do not feature in 
analysis. the plate was left in a cold room or fridge to 
allow it to set
lengths of rat aorta were stripped of fat and connective 
tissue, sprayed with 70% alcohol and immediately 
immersed in >20ml of saline. one millimetre-thick rings 
were cut and a single ring transferred to each of the 
matrigel coated wells
200μl of Medium 200 were added to each test well and 
surrounding wells were half-filled with phosphate 
buffered saline (PbS) to minimise water loss
After 2–3 days in the cell culture incubator, 200μl of test 
media were added when initial signs of outgrowth 
indicated a healthy explant. Honey dilutions were adjusted 
to account for the 200μl of medium already in the wells, 
but not the volume of gel under the cells
After a further 3–4 days, the outgrowths were ready for 
analysis. All plates were fixed with an excess of 5% 
formalin, which was washed extensively with water and 
stained with 0.5ml 0.01% methylene blue  
      
Adequate staining was achieved in 30 minutes, and the 
plates were washed and air dried. explants and their 
outgrowths were photographed under a low power 
stereo-zoom microscope (at ~40x overall magnification), 
allowing the entire well to be imaged
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angiogenesis assays
l aortic ring assay Again, the methodology is 
outlined in Table 1. Matrigel is an artificial basement 
membrane material of murine origin that is used as 
a substrate on which endothelial cells can 
differentiate and form tubular structures under 
appropriate (angiogenic) stimulation. For this study, 
frozen Matrigel (Becton-Coulter UK) was used. 
In a separate experiment, VEGF dilutions were 
used in order to demonstrate that a known ang-
iogenic stimulator was effective in the assay. 
Analysis was as for the Angiokit multi-well in vitro 
assay system (below) using the entire area of the 
outgrowth and using the same manufacturer’s Angi-
oSys software (TCS Cellworks) for analysis. 
l TcS cellworks angiokit This assay kit 
comprises multi-well plates with endothelial cells 
(probably fibroblasts of murine origin, the kit is 
patent protected) pre-seeded in a feeder layer, and a 
given laboratory protocol (see TCS Cellworks 
website for details). Following exposure to the 
honeys or control syrup at the concentrations given 
for each experiment and incubation for one week, 
the plate was fixed with ice cold 70% ethanol and 
the wells were stained immunochemically (e.g. for 
von Willebrand factor, which identifies endothelial 
cells from the feeder layer cells of mesodermal 
origin). After staining, the wells were photographed 
and analysed using AngioSys software (TCS 
Cellworks), which provides a number of measures of 
pseudotubule density length and branching. 
The method is too expensive to use routinely, but 
one plate was also run to assess the software’s ability 
to analyse images of aortic rings stained with methy-
lene blue in the previous angiogensis assay involving 
the frozen matrigel. Fig 1 illustrates the patterns of 
pseudotubule formation obtained using each system. 
Results were found to be comparable when checked 
against semi-subjective assessments — primarily 
manual counting of tubule intersection density on a 
jpeg image of the original preparation, estimating the 
area of outgrowth by projection onto paper, then cut-
ting out and weighing this area. 
Statistical analysis
Cytotoxicity data was obtained from eight replicates 
that were identified as normally distributed, with 
median values that were the same as arithmetic 
means. The experiment was duplicated, but Fig 2 
illustrates the means and standard errors from just a 
single run, as MTT colour development varied 
between experiments. 
Aortic ring assays were performed with duplicate 
wells and averaged. Complete experiments were 
performed three times. The number of wells per 
treatment was therefore small, however, curve-fit-
ting analysis (direct from the Excel spreadsheet) was 
applied so that the R2 value obtained reflected the 
consistency of all data points in conforming to a 
mathematically defined model, in this case a poly-
nomial equation — i.e., one with known variables, 
traditionally solved in mathematics by progressive-
ly eliminating them until only the ‘root’ remains.
Results
cytotoxicity
Only Activon showed a marked cytotoxic dose 
response over the range studied, with toxicity first 
rising at 0.32%v/v (Fig 2). Rowse honey only became 
marginally more toxic at 2.5%v/v, the highest dose 
given; the other two preparations were non-toxic at 
all doses. The standard errors are such that there are 
no statistically significant pair-wise differences 
between the three highest dose readings for Activon 
(R2 = 0.8275). 
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fig 2. cytotoxicity of honey preparations on monolayers of HuVec 
cells on plastic
results are plotted as the means and SeM of eight replicate wells. toxicity is calculated as 
100 minus the % residual viable biomass relative to untreated control wells
fig 1. Pseudotubule formation in the aortic ring and angiokit assays: well with 
aortic ring stained with methylene blue (a);  well of angiokit stained with daB 
(3.3’-diaminobenzidine) serving as chromogenic substrate for peroxidase-
conjugated antibodies against von willebrand factor
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fig 3. rat aortic ring assay results
Mean values for tubule density are plotted against serial dilutions of honeys, corrected by 
subtraction for the relevant artificial honey (sugar) controls. r2 value for polynomial curve-fit: 
rowse 0.982, Mesitran 0.843, Activon 0.680
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fig 4. rat aortic ring assay results
Mean values for total tubule length per unit area are plotted against serial dilutions 
of honeys, corrected by subtraction for the relevant artificial honey (sugar) 
controls. r2 values for polynomial curve-fit: rowse 0.942, Mesitran 0.0.681, 
Activon 0.573.
angiogenesis assays
l aortic ring assay Artificial honey showed no 
dose response other than a slight reduction in 
tubule formation at the higher concentrations (2.5 
and 5% v/v). Overall, treatment was close to that 
obtained with medium blanked wells. For instance, 
the total tubule length results were 10.3 ± 1.64 SEM 
for blanked wells and 9.2 ± 1.53 for artificial honey, 
and the tubule densities were 0.56 ± 0.18 and 0.65 ± 
0.19, respectively. 
Tubule formation was measured by two indices, 
one based on density (Fig 3) and one on total length 
(Fig 4); both are adjusted by subtracting the corre-
sponding values for artificial syrup dilution from 
the honey values. Results for all products tested 
were similar, showing a bell-shaped response curve, 
with the highest pro-angiogenic effect found at 
0.2% v/v honey. Comparable results were obtained 
with the other measures available from the software 
(node density and tubule area). 
In a separate experiment, a wide range of VEGF 
dilutions (in tenfold steps from 200ng/ml) and a 
range of Activon dilutions, known to cover peak 
pseudotubule stimulation, were run on the same 
plate. Tubule-formation curves are shown in Fig 5. 
Activon was chosen for this purpose as it was the 
most active product in the other assays and purified 
VEGF is expensive. The x-axis has been left unla-
belled as the two sets of dilutions are not directly 
comparable, although they cover the concentra-
tions of each agent, giving an in vitro pro-angiogenic 
response. These responses, measured on the y-axis, 
are comparable and show the honey to be as strong 
a stimulator of pseudotubule formation as VEGF in 
the aortic ring assay. It should be noted that aortic 
outgrowth is expressed relative to artificial honey 
data.
l TcS cellworks angiokit In the three plates 
used, honeys at dilutions of 0.2% and 0.04% were 
found to be pro-angiogenic. At 5% they were anti-
angiogenic, and at 1% neutral in their effect. 
Discussion
Wound healing is a complex sequence of coordinat-
ed events modified by delicately orchestrated path-
ways of cytokines and growth factors, that restore 
the structural integrity of damaged tissues.9 Honey 
has wound-healing properties, has no adverse 
effects on wound tissues and is cost-effective.10,11,12 
The antimicrobial and anti-inflammatory properties 
of honey initiate healing in recalcitrant wounds13 
by:
l Hastening sloughing of devitalised tissue
l Attracting macrophages to the wound bed
l Providing a local cellular energy source
l Counteracting malodour
l Promoting granulation and epithelialisation
l Protecting the wound from infection.14
Honey reduces inflammation at a molecular level, 
even in the absence of infection, which suggests 
that its anti-inflammatory effect is direct rather 
then a secondary consequence to clearing infection 
via its antibacterial activity.15 In vitro, it stimulates 
cultured monocytes to release cytokines,16 and acti-
vates the immune system by stimulating mitogene-
sis in B and T lymphocytes and activating neu-
trophils.17 It has been shown to stimulate the 
production of antibodies in mice exposed to 
Escherichia coli antigens.18 Several in vivo and in vitro 
studies have demonstrated its direct anti-inflamma-
tory activity19–21 and ability to decrease oxidative 
stress, by mopping up free radicals arising from 
research
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burns.22 Together, these studies indicate that honey 
possesses a broad-spectrum of activity that can posi-
tively impact on wound healing at a cellular level in 
in vitro models. However, other mechanisms 
involved in the promotion of rapid healing remain 
unidentified. It is unknown whether or not one 
therapeutic agent or a single process can ameliorate 
all issues of repair, or cover all vulnerabilities of 
impaired wound healing.9 
Although scant, the available evidence shows 
honey to be pro-angiogenic when applied to animal 
wounds.4,5 This may account for the clinically 
observed rapid development of granulation tis-
sue,23,24 as granules are fibroblasts growing at sites 
where there are capillary bundles supplying oxygen. 
The mechanism(s) by which honey might stimulate 
angiogenesis are unknown3 and with so little work 
published describing a pro-angiogenic effect, it 
would be premature to speculate extensively about 
modes of action at this time.
Topical application of hydrogen peroxide enhanc-
es cutaneous blood recruitment in ischaemic ulcers25 
and stimulates the proliferation of fibroblasts.26 As 
honey is diluted by wound exudate, it produces 
hydrogen peroxide by glucose oxidase. Honey also 
induces production of interleukin-6 (IL-6), 
interleukin-1β (IL-1β) and tumour necrosis factor-
alpha (TNF-α) in monocytes.16 The latter is a well-
established stimulator of angiogenesis.27 IL-6 is 
known to have a significant impact on wound heal-
ing16 and TNF-α exerts much of its beneficial effect 
by causing an increase in levels of IL-6.28 A synergis-
tic effect between these two cytokines has been 
indicated.29 Both TNF-α and IL-1β stimulate the 
release of various growth factors, including platelet-
derived growth factor and transforming growth 
factor-beta.30 
In this phenomenological study, we investigated 
the effect of three honey preparations and a sugar 
syrup (control) on angiogenesis using a rat aortic 
ring assay, validated by a TCS Cellworks Angiokit 
assay. Overall, our results suggest that honey is pro-
angiogenic at concentrations of 0.1–1.0%v/v. 
Despite the limited replication of experiments (due 
to the nature of the assay), the consistency of results 
across all three honey products lends weight to 
these results — all were pro-angiogenic within the 
same dose range, although the greatest effect was 
observed for Activon.
Dose responses to honey were best described by 
polynomial equations. The better fit was given by 
tubule density (Fig 3) where both Rowse and Mesi-
tran gave R2 values >0.8. Only Rowse gave a good 
curve-fit (R2 = 0.942) when tubule length was the 
criterion (Fig 4). Despite Rowse giving the best fit to 
a polynomial curve, it gave the least elevation of 
tubule formation; Activon yielded the highest peak. 
Clinically, the minimum inhibitory concentra-
tion of honey to prevent bacterial growth is 2%.15 
The Manuka-based Activon preparation was cyto-
toxic at this concentration when applied to mono-
cultures of HUVEC that were directly adherent to 
plastic. Since the concentration of hydrogen perox-
ide generated from diluted honey is very low com-
pared with that typically applied to a wound, any 
cytotoxic damage due to hydrogen peroxide would 
be minimal.31 The model described here is likely 
more sensitive in terms of cytotoxicity than an 
explant-based culture involving cooperating cell 
types,32 which is an option for the future. This also 
probably applies to the feeder-layer method repre-
sented by the Angiokit system.
The level of response that can be regarded as pro-
angiogenic was comparable to that achieved with a 
classical stimulator of angiogenesis, VEGF. This con-
trasts with the reported insensitivity of the HUVEC-
on-matrigel assay to VEGF,33 and is the main reason 
why rat aortic rings are, counter-intuitively, often 
preferred as an in vitro correlate of angiogenesis.34 
Although specialist medical grade honey prepara-
tions are generally more effective than blended 
commercial honeys, all produced a similar response 
curve in the rat aortic ring assay.
Fig 2 shows Activon to be toxic at higher concen-
trations. The apparent dip in toxicity at the highest 
concentration is not statistically significant, and is 
probably due to increased variance of optical densi-
ties when measuring low residual biomass.
Interestingly, the apparent pro-angiogenic effect 
of honey does not depend on sugar content. Indeed, 
artificial sugar syrup had no significant effect on the 
assays employed here. In other studies, sugar has 
been found to be less effective than honey in both 
reducing bacterial contamination and promoting 
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fig 5. comparison of pseudotubule formation curves by activon honey 
and VeGf. Total tubule length is plotted on the y-axis
5
the x-axis is logarithmic, the serial dilutions for veGF are tenfold, from log10 4.3 to 0.3pg/ml 
and for Activon 0.7 to -2.8%v/v in fivefold steps. both curves show a peak (2ng/ml for veGF 
and 1%v/v for Activon) with inhibition at higher concentrations. the control in this 
experiment was a medium blank, as indicated by the horizontal line
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wound healing.35,36 Sugar solution does not inhibit 
bacterial growth in vitro when compared with 
Manuka honey, which is effective at concentrations 
of just 5%.35 Furthermore, sugar solution by itself 
does not cause significant expression of cytokines in 
monocytes, whereas honey does stimulate them.16 
This suggests that the regulatory effects of honey 
could be due to components other than sugars. 
Honey has antimicrobial activities beyond the 
osmotic effect of its sugar content,3 but in a wound 
dressing context, the osmotic effect of sugary honey 
acting as a poultice and causing a net flow of solvent 
towards the wound surface means that any penetra-
tion of minor constituents into the wound bed 
would have to be against the fluid flow. 
Conclusion
Honey’s most attractive medicinal feature is perhaps 
its antimicrobial activity, which is likely free from 
bacterial resistance.37 However, other properties of 
honey are also important, at least in terms of the 
impact they may have on wound management. We 
believe that this study increases knowledge of the 
range of effects that honey can exert in a wound 
healing context, through indicating a stimulatory 
effect on angiogenesis. It seems there are possibili-
ties for both positive and negative effects on angio-
genesis, largely depending on the depth of penetra-
tion by its active constituents against an osmotic 
gradient. The extent to which this occurs deserves 
further investigation. n
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